Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma

Edwin R. Parra, MD, PhD, Pamela Villalobos, MD, Barbara Mino, BCs, and Jaime Rodriguez-Canales, MD

Abstract: Programmed cell death ligand 1 (PD-L1) is a major immune checkpoint protein that mediates antitumor immune suppression and response. Preliminary data suggest that its detection using immunohistochemistry (IHC) in formalin-fixed and paraffin-embedded tissues may predict clinical response to PD-1/PD-L1 therapy. In diagnostic pathology, it is essential to count with a validated IHC that can reliably detect PD-L1-positive cases. The present study was conducted to compare and validate different PD-L1 commercial clones and identify which ones can be reliably used by surgical pathologist to detect PD-L1 expression in human cancer tissues. Eight commercial available PD-L1 clones were tested and compared with a noncommercial PD-L1 antibody clone 5H1. Western blot and IHC using cell lines and human tissues were used to validate these clones. From all PD-L1 antibodies, only the clones E1L3N, E1J2J, SP142, 28-8, 22C3, and SP263 passed the Western blot and IHC validation, providing similar pattern than the clone 5H1 and then they were tested in 259 non–small cell lung cancer cases placed in 9 tissue microarrays. Among all cases, only those with ≥2 cores were included (185 cases). Positive and significant correlation was found between the median PD-L1 H-score in tumor and stroma compartments, for all selected antibodies. Overall, 56 of 185 cases were detected as positive cases in malignant cells expressing membranous PD-L1 by all the clones. However, the clone SP263 identified more PD-L1-positive cases compared with the other clones. Our results show that clones E1L3N, E1J2J, SP142, 28-8, 22C3, and SP263 provide positive membrane staining pattern comparable with clone 5H1. These commercial clones are comparable, but a careful evaluation by the pathologist is necessary to minimize error of positive misinterpretations.

Key Words: PD-L1, immunohistochemistry, Western blot, TMA lung cancer

Programmed cell death ligand 1 (PD-L1, also known as CD274 and B7-H1) is a major immune checkpoint protein that mediates antitumor immune suppression and response. Indeed, the importance of PD-L1-based immune suppression is highlighted by the advent of antiprogrammed death 1 (PD-1)/PD-L1 immunotherapies that have moved to the forefront of cancer treatment. PD-L1 is an immunomodulatory transmembrane glycoprotein of ~43 kDa (290 amino acids). The protein’s structure includes a short cytoplasmic domain, a membrane domain, and an extracellular domain. PD-L1 is a member of the B7 family of costimulatory molecules and his gene is mapped in chromosome 9p24.2.

Expression of PD-L1 was observed in macrophages from normal tissues, and could be upregulated in a large variety of cell types, such as antigen-presenting cells, B cells, T cells, epithelial cells, muscle cells, endothelial cells, and various malignant cells (MCs) lines. PD-L1 is differentially expressed across gestation by the trophoblast to induce fetal-maternal tolerance. Some studies also showed that PD-L1 is constitutively expressed on endothelial corneal cells protecting the eye from activated T cells to maintain the immune tolerance status.

The physiological role of PD-L1 is to bind PD-1 receptor expressed on the surface of activated cytotoxic T cells. This binding causes inhibition of interleukin-2 production and T-cell activation via reduction of the phosphorylation of 3-chain-associated protein kinase 70 and protein kinase C 0.13 PD-L1 expression has been observed and evaluated in MCs from several tumor types including, among others, melanoma, breast, colorectal, lung, and pancreatic cancers. The recent development...
of new agents blocking the interaction between PD-L1 and his receptor, PD-1, has opened a new therapeutic strategy. In routine practice, immunohistochemistry (IHC) analysis of PD-L1 expression using routinely processed histologic sections is essential to judge the eligibility of a patient for PD-1/PD-L1 immunotherapies and quantitative detection of its expression could be useful for monitoring the treatment responses. Furthermore, preliminary studies showed PD-L1 expression on human cancers using IHC in formalin-fixed and paraffin-embedded (FFPE) tissue samples may predict clinical response to PD-1/PD-L1 therapy. For this reason, in diagnostic pathology it is essential to count with a validated IHC that can reliably detect the real PD-L1-positive cases. Unfortunately, there are many PD-L1 commercial clones as well as different type of specimens used [whole histologic sections vs. tissue microarrays (TMAs)], type of protein expression analysis (IHC vs. immunofluorescence), and quantification assessment (image analysis vs. microscopic observation), which can provide different results, particularly important in clinical use.

An appropriate validation and evaluation of PD-L1 expression on tissues is important, because PD-L1 is currently regarded as a molecular target for immunotherapy on various malignant tumors. The present study was conducted to compare and validate the available commercial PD-L1 clones and identify which ones can be reliably used by the surgical pathologist to evaluate the IHC PD-L1 expression on FFPE specimens, using lung cancer as a model.

**TABLE 1.** Companion PD-L1 Assays Using to Detect PD-L1 Expression in NSCLC

| Antibody | Clone | Target Domain | Developer | Cut-off | Drug Related | References |
|----------|-------|---------------|-----------|---------|--------------|------------|
| 5H11     | Extracellular | Lieping Chen laboratory | ≥ 5% membranous staining of tumor cells | ND | Pembrolizumab | 26 |
| E1L3N    | Intracellular | Cell Signaling Technology | ≥ 5% membranous staining of tumor cells | ND | Pembrolizumab | 25 |
| E1J2J    | Extracellular | Cell Signaling Technology | ≥ 5 H-score | ND | Pembrolizumab | — |
| 22C3     | Extracellular | Dako | ≥ 1% membranous staining of tumor cells or immune cells that are intercalating or at the tumor interface* | Pembrolizumab | Pembrolizumab | 26 |
| SP142    | Intracellular | Ventana | Each specimen assigned a score based on both tumor and immune cell PD-L1 | Nivolumab (MPDL3280A) | Nivolumab | 27 |
| Genentech/Roche | TC3/IC3 PD-L1 ≥ 50% | Pembrolizumab | — |
| 28-8     | Extracellular | Dako | ≥ 5% membranous staining of tumor cells (minimum 100 cells evaluated) | Durvalumab (MEDI4736) | Durvalumab | 26,28 |
| SP263    | Extracellular | Bristol-Meyers Squibb | ≥ 25% membranous staining of tumor cells H-score | Pembrolizumab | Pembrolizumab | 26 |
| MedImmune/AstraZeneca | TC1/IC1 PD-L1 (1%-4%) | Pembrolizumab | — |

*The FDA indication in NSCLC for pembrolizumab requires cut-off ≥ 50%.
FDI indicates Food and Drug Administration; ND, no designation; NSCLC, non–small cell lung cancer; PD-L1, programmed cell death ligand 1.
reliable signal development on the same blot, we used Re-Blot detected on Kodak Biomax MR x-ray film (Kodak). For Chemiluminescence kit (Pierce Biotechnology). Signals were detected with anti-mouse or rabbit secondary antibody (Chemicon International) and enhanced with SuperSignal Carpinteria, CA, Kit cat#SK006) we used several dilutions of the study (E.R.P., J.R.-C., and P.V.).

**Image Acquisition and Digital Analysis**

To analyze and measure the IHC PD-L1 expression from positive and negative controls and TMA cases, the stained slides were digitally scanned using the Aperio ScanScope AT2 slide scanner (Leica Biosystems) and were captured with a ×20 objective. The images were visualized using ImageScope software (Leica Biosystems) and analyzed by 2 pathologists (E.R.P. and P.V.) using Aperio Image Toolbox analysis software (Aperio, Leica Biosystems). Only membranous cellular PD-L1 IHC expression on MCs, macrophages and lymphocytes, was considered as a positive PD-L1 expression in these different cells.

The pathologists who performed the image analysis (E.R.P. and P.V.) were blinded to PD-L1 antibodies used. Membranous PD-L1 expression on MCs (tumor compartment), and on tumor-associated inflammatory cells (TAICs, stroma compartment) were analyzed separately (Fig. 1) using a same cell membrane algorithm to each clone. The staining intensity scored as 0 (no staining), 1+ (weak staining), 2+ (moderate staining), or 3+ (strong staining), and extension (percentage) of expression were determined in both areas. PD-L1 H-score from each compartment was determined by multiplying the staining intensity and the percentage of positive cells (range, 0 to 300). Histology assessment of each TMA core was performed to ensure the presence tumor. TMA cores with at least 90% of MCs were included in the selected tumor compartment, and areas without malignant cells were included in the tumor-associated stroma compartment. The average of the median PD-L1 H-score from each case and from each compartment on the 3 cores of the TMA representing the same patient was expressed as final result. In addition, the pathologists (E.R.P. and P.V.) were blinded to PD-L1 antibodies used. The statistical software program IBM SPSS (version 22; Armonk, NY) was used to perform the computations for all analyses.

**Statistical Analyses**

The Spearman test was used to detect differences in continuous variables between the different antibodies. The statistical software program IBM SPSS (version 22; Armonk, NY) was used to perform the computations for all analyses.

**RESULTS**

**Validation of PD-L1 by WB**

For PD-L1 validation, several commercial clones were screened using WB with cell lysates preparing from tonsil, lung MCs lines, and PD-L1 nontransfected and transfected cells line. IHC validation, specificity, and applicability on the FFPE also were checked. These
FIGURE 1. Microphotographs of representative examples of the computer algorithm (Aperio toolbox) used to analyze the IHC PD-L1 expression (brown staining) in MCs on tumor compartment and TAICs on stroma compartment (A and B). Images of PD-L1 IHC expression processed using a manual segmentation of tumor and stroma compartments (left), membrane algorithm using to the analysis (upper and lower meddle) and image analysis quantification using the membrane algorithm by intensity in tumor compartment (upper right) and in the tumor and stroma compartments (lower right). IHC indicates immunohistochemistry; MCs, malignant cells; PD-L1, programmed cell death ligand 1; TAICs, tumor-associated inflammatory cells.
analyses gave important data about protein size and its expression. As shown in Figures 2A, B, the WB analysis showed a specific staining with a band in different lung cancer cell lines and HEK293 cell line transfected with PD-L1 gene by several commercial clones. The antibodies E1L3N, E1J2J, SP142, 28-8, and SP263, showed a molecular mass around 43 kDa, providing the same banding pattern observed with 5H1 clone. In addition, no band was observed in HEK293 cell line nontransfected with PD-L1 gene with the different clones. Unexpectedly, in human tonsil lysate tissue we observed a variable banding PD-L1 expression between clones. A molecular weight around 50 kDa band was observed with the PD-L1 clones E1L3N and E1J2J, also a band around 43 kDa was observed with the clones SP142 and SP263 and 2 molecular weights bands around 50 and 40 kDa were observed with the clones 28-8 and 5H1. In lung cancer cell lines, a positive banding pattern around 43 kDa was observed in 4 from 6 cell lines with the antibodies E1L3N, SP142, and 5H1 and 3 from 6 cell lines with the antibodies E1J2J, 28-8, and SP263. All these antibodies showed a correct band expression in the transfected cell lines with PD-L1 gene. For the other clones, EPR1161-2, 7G11, and rabbit polyclonal ab58810, unspecific and additional bands were detected (data not shown). Unfortunately, with the PD-L1 22C3 no band was observed on the WB with different dilutions tested in our hands.

Validation of PD-L1 by IHC

To the IHC validation, all clones were stained in FFPE tissues including, human reactive tonsil, human placenta, and cell blocks HEK293 cell line nontransfected and transfected with PD-L1 gene as positive and negative controls (Figs. 2A, B). The commercial clones, E1L3N, E1J2J, SP142, 28-8, 22C3, and SP263 showed a membrane staining and an identical staining pattern as 5H1 clone in the placenta and transfected cell line with PD-L1 gene. Similar membrane positivity in the reticulated epithelium of the tonsil crypts was observed with those clones. The disappearance of PD-L1 staining in the negative control (HEK293 cell line nontransfected with PD-L1 gene) was interpreted as evidence that the membrane pattern observed in the positive controls was specific and recognized the

![FIGURE 2. Western blot and microphotographs of representative examples from PD-L1 clones validation (A and B). PD-L1 MW area from human tonsil cell line, human lung cancer cell lines (H23, H157, H461, H4006, H1171, H193), HEK293, and HEK293-PD-L1 transfected are showing using PD-L1 E1L3N (A), E1J2J (B), SP142 (C), 28-8 (D), 22C3 (E), SP362 (F) 5H1(G) clones, and β-actin (H) by Western blot and immunohistochemistry. Positive membrane staining (brown) and negative PD-L1 staining are shown in reactive tonsil tissue, human placenta, cell pellet from HEK293-PD-L1 nontransfected and transfected cell line. HEK293 indicates human embryonic kidney 293 cell line; MW, molecular weight; PD-L1, programmed cell death ligand 1; transf., transfected.](https://example.com/figure2)
expected target. The other clones did not exhibit a specific membrane staining, showing some ones a massive expression through the entire cell population.

**IHC PD-L1 in TMA Cases**

Once the clones were validated by WB and IHC, it became feasible to characterize those protein expressions in TMA NSCLC tissues to determine the variations of PD-L1 expression between those selected clones. PD-L1 E1L3N, E1J2J, SP142, 28-8, 22C3, and SP362 showed a clear and positive membrane expression in many MCs, macrophages, and some lymphocytes in the TMA tissues. Although the heterogeneity and levels of expression varies from weak to strong and focal to diffuse in the different cells and cores from each case (Fig. 3). Our image analysis-based examination of tumor sections obtained from 122 ADC and 63 SCC patients demonstrated that the median PD-L1 H-score in the tumor compartment was 39.56 for E1L3N, 92.04 for E1J2J, 71.37 for SP142, 68.62 for 22-8, 36.48 for 22C3, and 63.32 for SP263, showing variability of intensity expression between the clones used (Table 2 and Fig. 3). Although we showed variability of IHC PD-L1 expression in the tumor and stroma compartments between the different antibodies, we observed a significant and positive correlation between clones (Fig. 4), although we observed a “r” < 0.500 between E1L3N, SP142 (intracellular domain), and SP263 (extracellular domain) in the tumor compartment. In addition, we determined the median percent value to assess IHC PD-L1 expressing by MCs in NSCLC patients. This median PD-L1 value in the

**FIGURE 3.** Microphotographs of representative examples of IHC PD-L1 heterogeneity expression in MCs from lung cancer specimens. Positive membrane staining (brown) and negative PD-L1 staining are shown with PD-L1 E1L3N, E1J2J, SP142, 28-8, 22C3, and SP362 clone. × 4 magnification and detail at × 200 magnification. IHC indicates immunohistochemistry; MCs, malignant cells; PD-L1, programmed cell death ligand 1.
tumor compartment was 28.34% with E1L3N, 81.90% with E1J2J, 55.98% with SP142, 57.65% with 28-8, 26.36% with 22C3, and 62.37% with SP263 clone (Table 3). Furthermore, using a partial or complete membranous staining at any intensity and ≥ 1% as positive MCs expression criteria under optical microscopy, the pathologists observed 67 positive cases with E1L3N, 71 positives cases with E1J2J, 78 positive cases with SP142, 69 positive cases with 28-8, 68 positives with 22C3, and 89 positives with SP263 clone (Table 4). Variability of positivity by the markers in the same case was also observed (Fig. 3) and the pathologists reviewers identified 54 positive cases to all the markers, 10 cases positives to 5 markers, 6 case positives to 4 markers, 3 cases positives to 3 markers, 9 cases positives to 2 markers, and 17 cases positives for only 1 marker. In addition, we determined the distribution of lung tumors using 2 cut-off percentages (5% and 50%), of MCs with PD-L1 expression as shown in the Table 4.

In the same way, we observed a variable distribution of PD-L1 in the stroma compartment expressing predominantly in lymphocytes and cells with macrophages characteristic. In the stroma compartment the median PD-L1 H-score from each compartment were determined by multiplying the staining intensity and the percentage of positive cell for each intensity (range, 0 to 300).

| Compartments | E1L3N | E1J2J | SP142 | 28-8 | 22C3 | SP263 |
|--------------|-------|-------|-------|------|------|-------|
| Tumor        | 39.56 ± 72.26 | 92.04 ± 48.32 | 71.37 ± 81.10 | 68.62 ± 57.09 | 36.48 ± 53.74 | 63.32 ± 72.92 |
| Stroma       | 71.88 ± 41.02 | 89.32 ± 31.29 | 138.80 ± 48.95 | 91.77 ± 38.92 | 60.76 ± 40.11 | 136.36 ± 37.99 |

PD-L1 H-scores from each compartment were determined by multiplying the staining intensity and the percentage of positive cell for each intensity (range, 0 to 300). PD-L1 indicates programmed cell death ligand 1.

**DISCUSSION**

The objective of this study was to compare and validate commercial PD-L1 clones and identify which ones can be reliably used by surgical pathologist. Also, we analyzed PD-L1 expression in a set of TMA NSCLC tissues to determine if there are differences in its expression using the validated PD-L1 antibodies.

An important issue for all tissue immunoprofiling is the specificity and sensitivity of the antibody clone. Currently, specificity is determined by several binding assays such as routinely used WB, immunoprecipitation, enzyme-linked immunosorbent assays, quantitative immunofluorescence, and in addition, IHC is applied to tissue controls and cell lines, in the validation process. The most frequently used method is the WB analysis, which yields confirmation of the size of the target and might give additional information about posttranslational modifications or the presence of splice variants or proteolytic fragments. The IHC was also important to determine the specific PD-L1 expression in human tissue. In this way, the WB analysis showed important information about the band and molecular size of the PD-L1 proteins tested especially from the commercial clones, E1L3N, E1J2J, SP142, 28-8, and SP263 that showed a molecular mass around 43kDa in several MCs lines and HEK293-transfected cell lines with the PD-L1 gene, providing the same banding pattern observed with 5H1 clone. The 5H1 monoclonal antibody has more recently been successfully applied to the staining of FFPE tumor tissues including lung cancer, renal cells carcinomas, cervical carcinoma, bladder cancer, and melanomas and it is the noncommercial clone very well validated in the literature. Although the cellular epitope target of those clones are different, E1J2J, 22C3, 28-8, and SP263 have its target in the extracellular domain and E1L3N and SP124 clones have its target in the intracellular domain; the 5 clones showed a specific membrane pattern and positive correlations between them in FFPE tissues. Indeed, the membrane domain is actually the active portion of the protein and the membranous staining is used as specific expression pattern by MCs in clinical evaluations. Once the clones were validated by WB and IHC in controls, PD-L1 E1L3N, E1J2J, SP142, 28-8, 22C3, and SP263 were staining in a set of TMA NSCLC. Although the level of expression ranged from weak to strong and from focal to diffuse on MCs with each clone, a specific membrane positive expression was not different between the clones. We also observed heterogenous PD-L1 expression from each individual clone when the same core was analyzed using the H-score or percentage of positive cells by image analysis assessment and this heterogeneity was detected not just in MCs but also in macrophages and lymphocytes, especially in the tumor compartment, showing that determination of a positive threshold is a difficult issue to consider when we are working with a no specific antibody that may be staining different types of cells. This can be maybe one of the factors that would explain the different results obtained in the literature, also considering the different methods of quantification (image analysis vs. microscopic observation), staining procedures (manually vs. automated staining vs. specific approved protocol), and different type of specimens used (whole histologic
sections vs. TMAs.\textsuperscript{37–40} The clinically relevant threshold for IHC PD-L1 expression in NSCLC cells has not yet been defined, and researchers have examined various cut-offs of PD-L1 positivity\textsuperscript{36; including, at least 1\%,\textsuperscript{41,42} 5\%,\textsuperscript{26,41,43–45} 10\%,\textsuperscript{28} and 50\%.\textsuperscript{27,42,46} of positive cells and greater than the median H-score.\textsuperscript{47} Although the heterogeneity and levels of expression in MCs were different among the cases, 29\% of cases were considered positives using PD-L1 E1L3N, E1J2J, 22C3, SP142, and 50\%.\textsuperscript{27,42,46}

\textbf{FIGURE 4.} Scatterplot showed the correlation of IHC PD-L1 H-score expression in the tumoral and stroma compartment between different clones. IHC indicates immunohistochemistry; PD-L1, programmed cell death ligand 1.
TABLE 3. Comparison of PD-L1 Using Percentage of Staining in Tumor and Stroma Compartments by Image Analysis-based Assessment

| Compartments | PD-L1 Percentage (Median and SD) |
|--------------|---------------------------------|
|              | E1L3N   | E1J2J   | SP142   | 28-8    | 22C3    | SP263   |
| Tumor        | 28.34 ± 32.23 | 81.90 ± 20.29 | 55.98 ± 33.01 | 57.65 ± 26.81 | 26.36 ± 29.51 | 62.37 ± 30.32 |
| Stroma       | 47.70 ± 21.32 | 72.71 ± 20.54 | 90.04 ± 15.27 | 70.04 ± 21.96 | 42.35 ± 23.01 | 92.44 ± 13.44 |

PD-L1 indicates programmed cell death ligand 1.

TABLE 4. Comparison of PD-L1 Expression in MCs in a TMA Non–Small Cells Lung Cancer Patients (N = 185)

| PD-L1 Clone | Different Cut-Offs of PD-L1 Expression on MCs by Microscopy Assessment (Number and %) |
|-------------|--------------------------------------------------------------------------------------------|
|             | ≥ 1%                                         | ≥ 5%                                         | ≥ 50%                                        |
|             | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative |
| E1L3N       | 67 (36)  | 118 (64) | 67 (36)  | 118 (64) | 65 (35)  | 120 (65) |          |          |
| E1J2J       | 71 (38)  | 114 (62) | 71 (38)  | 114 (62) | 70 (38)  | 115 (62) |          |          |
| SP142       | 78 (42)  | 107 (58) | 78 (42)  | 107 (58) | 75 (40)  | 110 (60) |          |          |
| 28-8        | 69 (37)  | 116 (63) | 69 (37)  | 116 (63) | 66 (36)  | 119 (64) |          |          |
| 22C3        | 68 (37)  | 111 (63) | 68 (37)  | 111 (63) | 64 (34)  | 121 (66) |          |          |
| SP263       | 89 (48)  | 92 (52)   | 89 (48)  | 92 (52)   | 80 (43)  | 105 (57) |          |          |

Positive PD-L1 expression, defined as ≥ 1%; ≥ 5% and ≥ 50% MCs membranous expression with partial or complete membrane staining at any intensity using the microscopy by a pathologist. MCs indicates malignant cells; PD-L1, programmed cell death ligand 1; TMA, tissue microarrays.

FIGURE 5. Microphotographs of representative examples of IHC PD-L1 heterogeneity expression in TAICs in TMA lung cancer specimens. Positive membrane staining (brown) in macrophages (A) and lymphocytes (B) are shown with PD-L1 E1L3N, E1J2J, SP142, 28-8, 22C3, and SP263 clone. × 4 magnification and detail at × 200 magnification. IHC indicates immunohistochemistry; PD-L1, programmed cell death ligand 1; TAICs, tumor-associated inflammatory cells; TMA, tissue microarrays.
IHC PD-L1 expression by TAICs in the tumor compartment. PD-L1, programmed cell death ligand 1; TAICs, tumor-associated inflammatory cells.

28-8, and SP263 clones under light microscopy using the most frequently cut-off used to assess IHC PD-L1 expression in MCs in NSCLC patients given PD-1/PD-L1 inhibitors: $\geq 1\%$. This cut-off value has been associated with durable tumor regression and prolonged disease stabilization in response to anti-PD-L1 treatment in advanced NSCLC cases. The SP263 clone detected more positive cases, 48%, following by SP142 with 42%, E1J2J with 38%, 28-8, and 22C3 with 37%, and E1L3N with 36%, being the clone which detected the less quantity of positive cases. The variability of positive or negative case detection by those clones in our study is probably related in part to the variability of affinity from each clone to detect cells expressing PD-L1, suggesting that the clones have a different power to binding the protein. Deterioration of PD-L1 antigen at bio-bank storage in tissue samples, saved for long periods of time, as has been showed with other antibodies\(^{48}\) maybe can explain in part some negative PD-L1 cases, which respond to therapy. The variation of the TMA cores along the different clones markers also need to be considered as important factor of limitation and variation showing the heterogenous staining pattern of those markers. In addition, our H-score image analysis from TAICs as macrophages in the stroma compartment showed also this heterogeneity of membrane expression and staining distribution through the different cases analyzed. The variability of PD-L1 distribution in these cells, exhibit again another factor that may be implicated in the different results observed in several studies by using different clones to detect PD-L1 expression when is observed in the entire population of cells expressing PD-L1. We believe that the more accurate method to analyze and quantify those markers is by a pathologist microscopic observation, using his knowledge and experience to identify only MCs’ expression following simple rules such as: to consider just membrane staining or reinforcement of membrane staining at any intensity as positive expression, to consider at least 100 MCs available in the tissue as the minimum number of cells required for analysis and finally report their quantifications as a percent of MCs positives to PD-L1. However, these results increased the necessity to standardized methodologies and validation techniques to report and to interpret the results of those markers as shown in literature\(^{25,49,50}\) as well as the necessity of new initiatives to homogenize the assays to address these problems\(^{51}\) and organized a joint effort between drug manufacturers and research people from different cancer organizations to creating a standard criterion to compare the performances of these PD-L1 assays.

In summary, after tests including WB and IHC on diverse controls and a NSCLC TMA we concluded that overall the clones, E1L3N, E1J2J, 22C3, SP142, 28-8, and SP263 show a similar staining membrane pattern as 5H1 clone in controls and in NSCLC cases. In our TMA, SP263 clone detected more positive cases than the other clones showing an individual positive variability of expression through the cases. Furthermore, more tests are necessary in different cancer tissues and whole section to understand much better the differences between the different clones used to detect PD-L1 expression.

ACKNOWLEDGMENTS

The authors thank Dr Lieping Chen at Yale University for kindly providing the antibody (5H1) to their validation and Dr Jie Qing Chen at MD Anderson Cancer Center to providing the cell line 293 transfected with the gene PD-L1.

REFERENCES

1. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.
2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
3. Ribas A, Tumeh PC. The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res. 2014;20:4892–4894.
4. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365–1369.
5. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034.
6. Keir ME, Butte MJ, Freemias GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
7. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 2002;20:29–53.
8. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239–245.
9. Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005;202:231–237.
10. Hori J, Wang M, Miyashita M, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol. 2006;177:5928–5935.
11. Watson MP, George AJ, Larkin DF. Differential effects of immunoinhibitory pathway modulation on corneal allograft survival. Invest Ophthalmol Vis Sci. 2006;47:3417–3422.
12. Sugita S, Usui Y, Horie S, et al. Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism. Invest Ophthalmol Vis Sci. 2009;50:263–272.
13. Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3 zeta signalosome and downstream signaling to PKC theta. *FEBS Lett.* 2004;574:37–41.

14. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. *Lancet.* 2014;383:816–827.

15. Dreeser RA, Hirt C, Vielh CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. *Eur J Cancer.* 2013;49:2233–2242.

16. Ghebre H, Mohamad S, Al-Omari A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. *Neoplasia.* 2006;8:190–198.

17. Bigelow E, Bevery KM, Xu H, et al. Immunochemistry of staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. *J Vis Exp.* 2013;71:e4059.

18. Lin C, Chen X, Liu J, et al. Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for non-small cell lung cancer. *Zhongguo fai zi za zhi.* 2014;17:734–740.

19. Parra ER, Behrens C, Rodriguez-Canales J, et al. Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung cancer patients. *Clin Cancer Res.* 2016;22:6278–6289.

20. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer—response. *Clin Cancer Res.* 2013;19:1021–1034.

21. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor microenvironment with response to anti-PD-1 therapy. *Clin Cancer Res.* 2014;20:5064–5074.

22. Berghoff AS, Ricken G, Widiham G, et al. PD-1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). *Clin Neuropathol.* 2014;33:42–49.

23. Bordeaux J, Walsh A, Agarwal S, et al. Antibody validation. *Biotechniques.* 2010;48:197–209.

24. Rimm D, Schalper K, Pusztai L. Unvalidated antibodies and misleading results. *Breast Cancer Res Treat.* 2014;147:457–458.

25. Ilie M, Hofman V, Dietel M, et al. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. *Virchows Arch.* 2016;468:511–525.

26. Boland JM, Kwon ED, Harrington SM, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. *Clin Lung Cancer.* 2013;14:157–163.

27. Feihrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet.* 2016;387:1837–1846.

28. Kim MY, Koh J, Kim S, et al. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. *Lung Cancer.* 2015;88:24–33.

29. Guo C, Shao R, Correa AM, et al. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. *J Thorac Oncol.* 2013;8:301–308.

30. Howat WJ, Lewis A, Jones P, et al. Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers. *Methods.* 2014;70:34–38.

31. Alganas C, Agaton C, Fagerberg L, et al. Antibody performance in western blot applications is context-dependent. *Biotechnol J.* 2014;9:435–445.

32. Thompson RH, Webster WS, Cheville JC, et al. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. *Urology.* 2005;66(suppl):10–14.

33. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. *Clin Cancer Res.* 2007;13(pt 2):709s–715s.

34. Karim R, Jordanova ES, Piersma SJ, et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. *Clin Cancer Res.* 2009;15:6341–6347.

35. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. *Curr Opin Immunol.* 2012;24:207–212.

36. Kerr KM, Nicolson MC. Non-small cell lung cancer, PD-L1, and the pathologist. *Arch Pathol Lab Med.* 2016;140:249–254.

37. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. *Clin Cancer Res.* 2004;10:5094–5100.

38. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. *Lab Invest.* 2014;94:107–116.

39. Yu H, Boyle TA, Zhou C, et al. PD-L1 expression in lung cancer. *J Thorac Oncol.* 2016;11:964–975.

40. Kerr KM, Tsao MS, Nicholson AG, et al. Committee IP. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? *J Thorac Oncol.* 2015;10:985–989.

41. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med.* 2015;373:123–135.

42. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med.* 2015;372:2018–2028.

43. D’Incecco A, Andreozzi M, Ludovini V, et al. PD-L1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. *Br J Cancer.* 2015;112:95–102.

44. Yang CY, Lin MW, Chang YL, et al. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. *Eur J Cancer.* 2014;50:1361–1369.

45. Rizvi NA, Mazieres J, Planchar D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *Lancet Oncol.* 2015;16:257–265.

46. Gatalica Z, Snyder C, Maney T, et al. Programmed cell death-1 ligand (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. *Cancer Epidemiol Biomarkers Prev.* 2014;23:2965–2970.

47. Smith J, Robida MD, Acosta K, et al. Quantitative and qualitative characterization of two PD-L1 clones: SP263 and E1L3N. *Diagn Pathol.* 2016;11:44.

48. Karlsson C, Karlsson MG. Effects of long-term storage on the detection of proteins, DNA, and mRNA in tissue microarray slides. *J Histochem Cytochem.* 2011;59:1113–1121.

49. Cree IA, Booton R, Cane P, et al. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. *Histopathology.* 2016;69:177–186.

50. Sholl LM, Aisner DL, Allen TC, et al. Programmed death ligand-1 immunohistochemistry—a new challenge for pathologists: a perspective from members of the Pulmonary Pathology Society. *Arch Pathol Lab Med.* 2016;140:341–344.

51. Rehman JA, Han G, Carvajal-Hausdorf DE, et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. *Modern Pathol.* 2017;30:340–349.